studies

Extensive stage SCLC (Es-SCLC), atezolizumab plus SoC vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpower-133, 2018 0.70 [0.54; 0.91] 0.70[0.54; 0.91]IMpower-133, 201810%403NAnot evaluable deaths (OS) (extension)detailed resultsIMpower-133, 2018 0.76 [0.60; 0.96] 0.76[0.60; 0.96]IMpower-133, 201810%403NAnot evaluable PFS (extension)detailed resultsIMpower-133, 2018 0.77 [0.63; 0.95] 0.77[0.63; 0.95]IMpower-133, 201810%403NAnot evaluable progression or deaths (PFS)detailed resultsIMpower-133, 2018 0.77 [0.62; 0.96] 0.77[0.62; 0.96]IMpower-133, 201810%403NAnot evaluable objective responses (ORR)detailed resultsIMpower-133, 2018 0.84 [0.56; 1.25] 0.84[0.56; 1.25]IMpower-133, 201810%403NAnot evaluable objective responses (ORR) (extension)detailed resultsIMpower-133, 2018 0.84 [0.56; 1.25] 0.84[0.56; 1.25]IMpower-133, 201810%403NAnot evaluable AE (any grade)detailed resultsIMpower-133, 2018 14.63 [0.82; 259.59] 14.63[0.82; 259.59]IMpower-133, 201810%394NAnot evaluable AE (grade 3-4)detailed resultsIMpower-133, 2018 1.16 [0.77; 1.76] 1.16[0.77; 1.76]IMpower-133, 201810%394NAnot evaluable AE leading to death (grade 5)detailed resultsIMpower-133, 2018 0.35 [0.11; 1.11] 0.35[0.11; 1.11]IMpower-133, 201810%394NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMpower-133, 2018 3.96 [1.57; 9.99] 3.96[1.57; 9.99]IMpower-133, 201810%394NAnot evaluable SAE (any grade)detailed resultsIMpower-133, 2018 1.12 [0.74; 1.70] 1.12[0.74; 1.70]IMpower-133, 201810%394NAnot evaluable STRAE (any grade)detailed resultsIMpower-133, 2018 1.26 [0.78; 2.06] 1.26[0.78; 2.06]IMpower-133, 201810%394NAnot evaluable TRAE (any grade)detailed resultsIMpower-133, 2018 1.56 [0.68; 3.56] 1.56[0.68; 3.56]IMpower-133, 201810%394NAnot evaluable TRAE (grade 3-4)detailed resultsIMpower-133, 2018 1.02 [0.68; 1.52] 1.02[0.68; 1.52]IMpower-133, 201810%394NAnot evaluable TRAE leading to death (grade 5)detailed resultsIMpower-133, 2018 0.99 [0.20; 4.96] 0.99[0.20; 4.96]IMpower-133, 201810%394NAnot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsIMpower-133, 2018 3.99 [0.18; 89.04] 3.99[0.18; 89.04]IMpower-133, 201810%394NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsIMpower-133, 2018 0.99 [0.02; 50.14] 0.99[0.02; 50.14]IMpower-133, 201810%394NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsIMpower-133, 2018 0.99 [0.02; 50.14] 0.99[0.02; 50.14]IMpower-133, 201810%394NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsIMpower-133, 2018 1.18 [0.66; 2.12] 1.18[0.66; 2.12]IMpower-133, 201810%394NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsIMpower-133, 2018 3.99 [0.18; 89.04] 3.99[0.18; 89.04]IMpower-133, 201810%394NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsIMpower-133, 2018 1.98 [0.07; 59.51] 1.98[0.07; 59.51]IMpower-133, 201810%394NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsIMpower-133, 2018 3.99 [0.18; 89.04] 3.99[0.18; 89.04]IMpower-133, 201810%394NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsIMpower-133, 2018 0.99 [0.02; 50.14] 0.99[0.02; 50.14]IMpower-133, 201810%394NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsIMpower-133, 2018 4.02 [0.45; 36.30] 4.02[0.45; 36.30]IMpower-133, 201810%394NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsIMpower-133, 2018 3.00 [0.31; 29.09] 3.00[0.31; 29.09]IMpower-133, 201810%394NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsIMpower-133, 2018 0.48 [0.18; 1.30] 0.48[0.18; 1.30]IMpower-133, 201810%394NAnot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsIMpower-133, 2018 1.98 [0.07; 59.51] 1.98[0.07; 59.51]IMpower-133, 201810%394NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsIMpower-133, 2018 6.02 [0.30; 120.88] 6.02[0.30; 120.88]IMpower-133, 201810%394NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsIMpower-133, 2018 0.99 [0.02; 50.14] 0.99[0.02; 50.14]IMpower-133, 201810%394NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsIMpower-133, 2018 0.99 [0.02; 50.14] 0.99[0.02; 50.14]IMpower-133, 201810%394NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsIMpower-133, 2018 0.99 [0.02; 50.14] 0.99[0.02; 50.14]IMpower-133, 201810%394NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsIMpower-133, 2018 4.02 [0.45; 36.30] 4.02[0.45; 36.30]IMpower-133, 201810%394NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsIMpower-133, 2018 1.25 [0.48; 3.24] 1.25[0.48; 3.24]IMpower-133, 201810%394NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsIMpower-133, 2018 0.99 [0.06; 15.94] 0.99[0.06; 15.94]IMpower-133, 201810%394NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsIMpower-133, 2018 1.98 [0.07; 59.51] 1.98[0.07; 59.51]IMpower-133, 201810%394NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsIMpower-133, 2018 0.91 [0.57; 1.44] 0.91[0.57; 1.44]IMpower-133, 201810%394NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsIMpower-133, 2018 0.49 [0.04; 5.47] 0.49[0.04; 5.47]IMpower-133, 201810%394NAnot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsIMpower-133, 2018 0.33 [0.03; 3.17] 0.33[0.03; 3.17]IMpower-133, 201810%394NAnot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsIMpower-133, 2018 3.99 [0.18; 89.04] 3.99[0.18; 89.04]IMpower-133, 201810%394NAnot evaluable Pneumonia TRAE (grade 3-4)detailed resultsIMpower-133, 2018 6.02 [0.30; 120.88] 6.02[0.30; 120.88]IMpower-133, 201810%394NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsIMpower-133, 2018 0.49 [0.04; 5.47] 0.49[0.04; 5.47]IMpower-133, 201810%394NAnot evaluable Rash TRAE (grade 3-4)detailed resultsIMpower-133, 2018 8.06 [0.42; 153.52] 8.06[0.42; 153.52]IMpower-133, 201810%394NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsIMpower-133, 2018 0.99 [0.02; 50.14] 0.99[0.02; 50.14]IMpower-133, 201810%394NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsIMpower-133, 2018 1.36 [0.67; 2.73] 1.36[0.67; 2.73]IMpower-133, 201810%394NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsIMpower-133, 2018 0.66 [0.11; 3.97] 0.66[0.11; 3.97]IMpower-133, 201810%394NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-10-31 23:57 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 281,194,162,172 - treatments: 866